Comparing Prime Medicine (PRME) and Its Peers

Prime Medicine (NYSE:PRME) is one of 253 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Prime Medicine to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Institutional & Insider Ownership

47.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 24.3% of Prime Medicine shares are owned by insiders. Comparatively, 17.1% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Prime Medicine and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Prime Medicine	$5.21 million	-$121.82 million	-3.44
Prime Medicine Competitors	$472.45 million	$90.60 million	-2.34

Prime Medicine’s competitors have higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Prime Medicine and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0	1	4	0	2.80
Prime Medicine Competitors	1220	4024	10189	148	2.59

Prime Medicine currently has a consensus price target of $21.60, indicating a potential upside of 210.79%. As a group, “Biological products, except diagnostic” companies have a potential upside of 76.60%. Given Prime Medicine’s stronger consensus rating and higher possible upside, equities analysts plainly believe Prime Medicine is more favorable than its competitors.

Profitability

This table compares Prime Medicine and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-67.28%	-57.83%
Prime Medicine Competitors	-5,007.71%	-294.35%	-48.23%

Summary

Prime Medicine beats its competitors on 7 of the 12 factors compared.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.